A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

This study is looking at how safe and tolerable a new medicine, talquetamab, is when used with other cancer treatments for people with multiple myeloma. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow. The study will help figure out the best dose of talquetamab when used with other medicines.

To join, participants must have been diagnosed with multiple myeloma and meet certain health criteria. Women who can have children need to have a pregnancy test before joining. The study is not for people who have recently had certain vaccines, taken a lot of steroids, or have specific health conditions.

• Study Length: The study is ongoing, but the exact duration for participants isn't specified.
• Visits: Regular visits to the study site are required to monitor health and treatment effects.
• Risks: There may be risks associated with the treatment, such as side effects from the medicine.

Participants will need to follow certain lifestyle guidelines during the study. If interested, talk to your doctor to see if you qualify and to understand any potential benefits or risks.